Cancer specific gene MG20
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Jul 14, 2005
app pub date -
Jan 7, 2005
filing date -
Jan 9, 2004
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Abstract
MG20 (CCNDBP1) is identified as an oncogene. Methods and compositions for detecting and diagnosing cancer in patients are provided, by determining the level of MG20 expression in biological samples. Also provided are methods for screening for inhibitors and moderators of MG20 expression and activity, as well as compositions comprising compounds and molecules that inhibit or moderate MG20 expression or activity, thereby treating cancer, in vivo.
First Claim
Family
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Advertisement
Advertisement
Advertisement
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully